

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Single cell sequencing analysis uncovers genetics-influenced CD16+monocytes and memory CD8+T cells involved in severe COVID-19

Yunlong Ma^{1,†}, Fei Qiu^{1,†}, Chunyu Deng^{1,†}, Jingjing Li^{2,†}, Yukuan Huang^{1,†}, Zeyi Wu¹, Yijun Zhou¹, Yaru Zhang¹, Yichun Xiong³, Yinghao Yao³, Yigang Zhong⁴, Jia Qu¹, Jianzhong Su^{1,3*}

¹ Institute of Biomedical Big Data, School of Ophthalmology & Optometry and Eye Hospital, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, 325027, China.

² State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China.

³ Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325011, China.

⁴ Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University school of Medicine, Hangzhou, China.

[†] These authors contributed equally to this work.

***Correspondence should be addressed to:**

Jianzhong Su: sujz@wmu.edu.cn;

¹ Institute of Biomedical Big Data, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.

³ Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325011, China.

Abstract

Background: Understanding the host genetic architecture and viral immunity contributes to the development of effective vaccines and therapeutics for controlling the COVID-19 pandemic. Alterations of immune responses in peripheral blood mononuclear cells play a crucial role in the detrimental progression of COVID-19. However, the effects of host genetic factors on immune responses for severe COVID-19 remain largely unknown.

Methods: We constructed a powerful computational framework to characterize the host genetics-influenced immune cell subpopulations for severe COVID-19 by integrating GWAS summary statistics (N = 969,689 samples) with four independent scRNA-seq datasets (N = 606,534 cells).

Results: We found that 34 risk genes were significantly associated with severe COVID-19, and the number of highly-expressed genetics-risk genes increased with the severity of COVID-19. Three cell-subtypes that are CD16⁺monocytes, megakaryocytes, and memory CD8⁺T cells were significantly enriched by COVID-19-related genetic association signals. Notably, three causal risk genes of *CCR1*, *CXCR6*, and *ABO* were specifically expressed in these three cell types, respectively. *CCR1*⁺CD16⁺monocytes and *ABO*⁺ megakaryocytes with significant up-regulated genes including *S100A12*, *S100A8*, *S100A9*, and *IFITM1* confer higher risk to the cytokine storms among severe patients. *CXCR6*⁺ memory CD8⁺ T cells exhibit a notable polyfunctionality of multiple immunologic features, including elevation of proliferation, migration, and chemotaxis. Moreover, we observed a prominent increase in cell-cell interactions of both *CCR1*⁺ CD16⁺monocytes and *CXCR6*⁺ memory CD8⁺T cells in severe patients compared to normal controls among both PBMCs and lung tissues, and elevated interactions with epithelial cells could contribute to enhance the resident to lung airway for against COVID-19 infection.

Conclusions: We uncover a major genetics-modulated immunological shift between mild and severe infection, including an increase in up-regulated genetic-risk genes, excessive secreted inflammatory cytokines, and functional immune cell subsets contributing high risk to severity,

51 which provides novel insights in parsing the host genetics-influenced immune cells for severe
52 COVID-19.

53 **Keywords:** Single cell sequencing, GWAS, immune cells, inflammatory storm, COVID-19

54

55

Background

56 The coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory
57 syndrome coronavirus 2 (SARS-CoV-2), has widely and severely jeopardized the health and
58 economy systems of most countries worldwide. As of July 21th, 2021, there were more than 192.2
59 million confirmed patients with more than 4.12 million deaths in the whole world [1]. COVID-19
60 has distinct clinical manifestations ranging from asymptomatic to severe respiratory failure [2].
61 Mortalities of COVID-19 are largely derived from severe patients with interstitial pneumonia in
62 both lungs and acute respiratory distress syndrome [3]. Many earlier studies [4-6] have shown that
63 the number of severe COVID-19 patients who are elders and have comorbidities, such as diabetes
64 and hypertension, has increased. In this connection, understanding the immunologic mechanism of
65 severe COVID-19 and identifying novel vaccine targets to control the pandemic are of considerable
66 interest.

67 Accumulating evidence have suggested that alterations of immune responses in peripheral
68 blood mononuclear cells (PBMCs) and bronchoalveolar lavage fluid (BALF) play a crucial role in
69 the detrimental progression of COVID-19 [7, 8]. There has been evidence that cytokine storm,
70 usually found in severe COVID-19 patients, causes the adverse progression of COVID-19 [7].
71 Increased circulating levels of proinflammatory cytokine, including IL-10, IL-6 and TNF- α , have
72 been reported to be associated with severe COVID-19 [7, 9]. Single-cell RNA sequencing (scRNA-
73 seq) has been extensively utilized to reveal the immune responses of COVID-19 patients in both
74 lung and peripheral blood [10-18]. Megakaryocytes and monocytes [11, 12], T cells exhaustion
75 [14], lymphopenia [19], and increased levels of cytokines [20] may cause aberrant peripheral

76 immune activities in severe COVID-19 patients. Based on large-scale samples, previous studies
77 identified that dysregulation of mTOR signaling pathway in dendritic cells [21] and aberrant
78 myeloid cell subpopulations [16, 17] implicated in severe COVID-19. Su et al. [10] revealed an
79 increase in inflammation and a sharp drop in blood nutrients between mild and moderate-to-severe
80 COVID-19, and new subsets of immune cells emerged in moderate COVID-19 patients.

81 Genome-wide association study (GWAS) has emerged as a powerful approach to identify risk
82 genes and genetic variants for complex diseases. By gathering population-based GWAS data
83 worldwide, the COVID-19 Host Genetic Consortium has launched the “COVID-19 Host Genetics
84 Initiative” project to facilitate COVID-19 host genetic research and identify genetic determinants
85 of COVID-19 [22]. Subsequently, a growing number of GWASs have identified numerous
86 significant genetic variants associated with COVID-19 susceptibility and severity [23-28].
87 Ellinghaus et al. [27] performed a meta-analysis of two independent GWAS datasets with 1,610
88 severe COVID-19 patients and 2,205 matched controls at seven hospitals in the Italian and Spanish
89 epicenters, and identified two susceptibility loci of 3p21.31 and 9q34.2 to be significantly
90 associated with severe COVID-19 at the genome-wide level. Based on a large-scale meta-analysis
91 (N = 680,128), our group found that the *IFNAR2-IL10RB* gene cluster were significantly associated
92 with COVID-19 susceptibility, and suggested that *IFNAR2* and *IL10RB* might have regulatory roles
93 in the pulmonary immune response based on scRNA-seq data [25]. Consistently, Pairo-Gastineira
94 et al. [24] conducted a GWAS study based on 2,244 critically ill COVID-19 patients and highlighted
95 that several genes including *IFNAR2*, *DPP9*, and *OAS1* were significantly associated with severe
96 COVID-19 at a genome-wide significance.

97 Two primary hypotheses were proposed for the involvement of immune genes in severe
98 COVID-19 susceptibility. Whether the severe COVID-19-related risk genes associated with
99 defective innate immune responses would induce persistent viral replication and resultant high viral
100 loads, and whether an exaggerated genetically-mediated cytokine production contributes to the

101 hyper-inflammation and poor outcome among severe COVID-19. However, the effects of these
102 genetic determinants on the peripheral immune cells for severe COVID-19 remain largely unknown.
103 In view of a purely genetic study or single cell sequencing study cannot address this critical question,
104 we here leveraged comprehensive computational methods to combine a large-scale GWAS
105 summary dataset with scRNA-seq data for identifying host genetics-influenced immune cell
106 subpopulations involved in the etiology of severe COVID-19.

108 **Methods**

109 *Single cell RNA-seq data on severe COVID-19*

110 In this study, we downloaded four independent scRNA-seq datasets on COVID-19 in PBMC
111 and BALF from the ArrayExpress database (Dataset #1, the accession number is E-MTAB-9357
112 from Su et al. study [10]), and the Gene Expression Omnibus (GEO) database (Dataset #2, the
113 accession number is GSE149689 from Lee et al. study [18], Dataset #3, the accession number is
114 GSE150861 from Guo et al. study [11], and Dataset #4, the accession number is GSE158055 [29]).
115 The first dataset contained 270 peripheral blood samples including 254 samples with different
116 COVID-19 severity (i.e., mild N = 109, moderate N = 102, and severe N = 50) and 16 healthy
117 controls for scRNA-seq analysis. There were eight patients in dataset #2 with COVID-19 of varying
118 clinical severity, including asymptomatic, mild, and severe, and four healthy controls with PBMCs.
119 The dataset #3 included five peripheral blood samples collected from two severe COVID-19
120 patients at three different time points during tocilizumab treatment, containing two different stages:
121 severe stage and remission stage. Within the dataset #4, 12 BALF samples were collected from
122 lung tissues, including three moderate and nine severe patients. For all the datasets, the sample
123 collection process were reviewed and approved by Institutional Review Board at the institutions
124 where samples were originally collected. The COVID-19 severity was evaluated by using the World
125 Health Organization (WHO) ordinal scale (WOS), the National Early Warning Score (NEWS), or

126 the Diagnosis and Treatment of COVID-19 (Trail Version 6). Single-cell transcriptomes for these
127 four datasets were gathered using the 10× Genomics scRNA-seq platform.

129 *Single cell RNA sequencing data processing*

130 We performed normalization, clustering, and dimensionality reduction, differential expression
131 gene (DEG) analysis, and visualization on these four independent scRNA-seq datasets with the
132 Seurat R package [30]. The *SCTransform* function was used to scale and transform data, and linear
133 regression model was applied to omit redundant variations caused by cellular complexity (i.e., cells
134 expressed less than 200 genes or more than 2,500 genes were removed) or cellular quality (i.e.,
135 cells that had UMIs more than 10,000 and expressed reads of mitochondrial genes greater than 10%
136 were removed). The *CellCycleSoring* function was applied to remove the effects of confounding
137 factors. Principal component analysis (PCA) was carried out to extract principal components (PCs)
138 that could explain most of datasets via using high variable genes. Top 20 PCs were utilized to
139 conduct uniform manifold approximation and projection (UMAP) to embed the dataset into two
140 dimensions. Subsequently, we constructed a shared nearest-neighbor graph (SNN) using the
141 *FindNeighbors* function based on the top 20 PCs, and applied a graph-based modularity-
142 optimization algorithm from the Louvain method [31] on this SNN for clustering the dataset with
143 the cluster resolution set to 0.5. We used the *RunHarmony* function with PCA reduction method
144 from harmony R package [32] to integrate samples to correct batch effects. The
145 *FindConservedMarkers* function in Seurat was implemented to find differential expressed genes
146 for determining cellular identity. Well-defined markers were used to annotate clusters, and
147 uncharacterized clusters in the first round of clustering were extracted to run the second round of
148 clustering (Supplemental Table S2). A total of 606,534 cells with 563,856 PBMC cells and 42,678
149 BALF cells were yielded from 300 samples based on the four independent scRNA-seq datasets
150 (Supplemental Table S1 and Figure 1A). To allow comparison across samples and datasets, we

151 used a common dictionary of gene symbols to annotate genes and these unrecognized symbols were
152 removed.

153

154 ***GWAS summary data on hospitalized COVID-19***

155 The meta-GWAS summary data on severe COVID-19 round 4 (B2_ALL, Susceptibility
156 [Hospitalized COVID-19 vs. Population]) were downloaded from the official website of the
157 COVID-19 Host Genetic Consortium [22] (<https://www.covid19hg.org/>; analyzed file named:
158 “COVID19_HGI_B2_ALL_leave_23andme_20201020.txt.gz”; released date of October 4 2020).
159 There were 7,885 hospitalized COVID-19 patients and 961,804 control participants from 21
160 independent contributing studies. There was an overwhelming majority of participants in these
161 contributing studies with European ancestry (93%). The meta-GWAS summary statistics contained
162 P values, Wald statistic, inverse-variance meta-analyzed log Odds Ratio (OR) and related standard
163 errors. The 1,000 Genomes Project European Phase 3 [33] was used as a panel for pruning. Results
164 from 23&Me cohort GWAS summary statistics were excluded from our current analysis. Genetic
165 variants without RefSNP number in the Human Genome reference builds 37 were filtered out,
166 giving a total of 9,368,170 genetic variants satisfying the major allele frequency (MAF) over 0.0001
167 and the imputation score of greater than 0.6. We used the *qqman* R package to figure both Manhattan
168 plot and quantile-quantile (QQ) plot, and the web-based software of *LocusZoom*
169 (<http://locuszoom.sph.umich.edu/>)[34] to visualize the regional association plots for significant risk
170 loci.

171

172 ***Hierarchical clustering analysis***

173 To examine the similarity of the transcriptome profiles between cell types across different
174 COVID-19 severities (Supplemental Figure S4), we merged the counts of UMI for each cell type
175 according to normal, mild, moderate, and severe COVID-19. In order to normalize gene expression,

176 we divided the counts of UMI for each gene by the counts of total UMI for all genes in each cell
177 type and then multiplied by 100,000, as refer to the method in a previous study [18]. A median
178 expression value of greater than 0.5 was used to calculate the relative change in each gene
179 expression by dividing it by the median value for each gene, and the Pearson correlation coefficient
180 (PPC) of the relative change in gene expression was used for current hierarchical clustering analysis.

181

182 ***Gene-based association analysis***

183 To perform a gene-based genetic association analysis of the meta-GWAS summary statistics
184 on severe COVID-19, we leveraged the updated SNP-wise Mean model of MAGMA [35]. In this
185 model, MAGMA computes a test statistic:

$$186 \quad T = \sum_i^N Z_i^2 = \mathbf{Z}^T \mathbf{Z}$$

187 where N is the number of SNPs mapped in a gene and $Z_i = \Phi(p_i)$. Of note, Φ is the cumulative
188 normal distribution function and p_i is the marginal P value for a given SNP i . SNPs belonging to
189 a specific gene were based on whether located in the gene body or within the +/- 20 kb upstream or
190 downstream region of the gene. Furthermore, the model assumes $\mathbf{Z} \sim \text{MVN}(\mathbf{0}, \mathbf{S})$, where \mathbf{S} is the
191 LD matrix of the SNP genotypes. The LD matrix can be diagonalized and hence written as
192 $\mathbf{S} = \mathbf{Q}\mathbf{A}\mathbf{Q}^T$, where \mathbf{Q} is an orthogonal matrix and $\mathbf{A} = \text{diag}(\lambda_1, \lambda_2, \dots, \lambda_N)$ with λ_j being the j th
193 eigenvalue of \mathbf{S} . The 1,000 Genomes Project Phase 3 European Panel [33] was used for calculating
194 the LD information among SNPs extracted from GWAS summary data on COVID-19.
195 $\mathbf{D} \sim \text{MVN}(\mathbf{0}, \mathbf{I}_K)$ is a random variable, where $\mathbf{D} = \mathbf{A}^{-0.5} \mathbf{Q}^T \mathbf{Z}$. Then the sum of squared SNP Z-
196 statistics as the following formula:

$$197 \quad T = \mathbf{Z}^T \mathbf{Z} = (\mathbf{Q}\mathbf{A}^{0.5} \mathbf{D})^T \mathbf{Q}\mathbf{A}^{0.5} \mathbf{D} = \mathbf{D}^T \mathbf{A} \mathbf{D} = \sum_i^N \lambda_i D_i^2$$

198 with $D_i \sim N(0,1)$ and $D_i^2 \sim \chi_1^2$. Namely, T follows a mixture distribution of independent χ_1^2
199 random variables. A total of 19,138 genes were included in the current analysis. We used the
200 Benjamini-Hochberg false discovery rate (FDR) method, in which a gene with a $FDR \leq 0.05$ ($P \leq$
201 6.8×10^{-5}) was interpreted as significant, to adjust for multiple testing.

202

203 ***Pathway enrichment analysis***

204 We applied the *built-in* functions of MAGMA [35], using the results from GWAS summary
205 statistics as its input, to examine genome-wide enriched biological pathways for severe COVID-19.
206 We calculated competitive P values by examining the results that the combined effect of genes
207 within a pathway is significantly greater than the combined effect of all other genes, and 10,000
208 permutations was used to adjust competitive P values. Additionally, we leveraged the over-
209 representation algorithm of the WebGestalt (<http://www.webgestalt.org>) [36] along with the
210 significant genes as an input list to conduct a pathway enrichment analysis using the KEGG
211 pathway resource [37]. The number of genes in each pathway was set to between 5 and 2,000, and
212 the Benjamini-Hochberg FDR was used for multiple correction. To cluster these identified KEGG
213 pathways, we performed a multidimensional scaling (MDS) analysis based on the Jaccard distance
214 method [38], and constructed a pathway-pathway interaction network for these significantly
215 enriched pathways setting the Jaccard distance > 0.1 .

216

217 ***Combining GWAS-based genetic signals with eQTL data***

218 To uncover genetically-regulatory expression of genes associated with severe COVID-19, we
219 conducted an integrative genomics analysis by using the S-PrediXcan [39] by combining meta-
220 GWAS summary statistics with expression quantitative trait loci (eQTL) data for 49 tissues from
221 the GTEx Project (version 8). S-PrediXcan mainly uses two linear regression models to analyze the
222 association between predicted gene expression and severe COVID-19:

223
$$Y = \alpha_1 + X_l \beta_l + \varepsilon_1$$

224
$$Y = \alpha_2 + G_g \gamma_g + \varepsilon_2$$

225 where α_1 and α_2 are intercepts, ε_1 and ε_2 are independent error terms, Y is the n dimensional
 226 vector for n individuals, X_l is the allelic dosage for SNP l in n individuals, β_l is the effect size
 227 of SNP l , $G_g = \sum_{i \in \text{gene}(g)} \omega_{ig} X_i$ is the predicted expression calculated by ω_{ig} and X_l , in which
 228 ω_{ig} is derived from the GTEx Project, and γ_g is the effect size of G_g . The Z-score (Wald-statistic)
 229 of the association between predicted gene expression and severe COVID-19 can be transformed as:

230
$$Z_g = \frac{\hat{\gamma}_g}{\text{se}(\hat{\gamma}_g)} \approx \sum_{i \in \text{gene}(g)} \omega_{ig} \frac{\hat{\sigma}_i}{\hat{\sigma}_g} \frac{\hat{\beta}_i}{\text{se}(\hat{\beta}_i)}$$

231 where $\hat{\sigma}_g$ is the standard deviation of G_g and can be calculated from the 1,000 Genomes Project
 232 European Phase 3 Panel, $\hat{\beta}_i$ is the effect size from GWAS on COVID-19 and $\hat{\sigma}_i$ is the standard
 233 deviation of $\hat{\beta}_i$. S-PrediXcan was run for each of 49 tissues with 659,158 gene-tissue pairs.

234 Furthermore, to increase the power to discover significant genes whose expression has similar
 235 regulations across multi-tissues, we utilized the S-MultiXcan [40] to meta-analyze these results
 236 from above S-PrediXcan analysis. S-MultiXcan fits a linear regression model of severe COVID-19
 237 on predicted expression from multiple tissue models jointly:

238
$$Y = \sum_{j=1}^p T_j g_j + e = Tg + e$$

239 where $\tilde{T}_j = \sum_{i \in \text{gene}(j)} \omega_i X_i$ is the predicted expression of tissue j , and T_j is the standardization of
 240 \tilde{T}_j to *mean* = 0 and *standard deviation* = 1. g_j is the effect size for the predicted gene expression
 241 in tissue j , e is an error term with variance σ_e^2 , and p is the number of included tissues. There
 242 were 22,326 genes across 49 GTEx tissues with integrated convergent evidence in S-MultiXcan,
 243 and a gene with a value of $\text{FDR} \leq 0.05$ ($P \leq 3.8 \times 10^{-5}$) is considered to be significant.

244

245 ***In silico permutation analysis***

246 To explore the concordance of results from both MAGMA analysis (Gene set #1: $N = 944$, P
247 ≤ 0.05) and S-MultiXcan analysis (Gene set #2: $N = 1,274$, $P \leq 0.05$), we performed an *in silico*
248 permutation analysis which consisted 100,000 times (N_{Total}) random selections [41, 42]. We first
249 calculated the number of overlapped genes between Gene Set #1 and #2 ($N_{Observation} = 302$), then
250 employed the total number of genes in S-MultiXcan analysis as background genes ($N_{Background} =$
251 $22,326$). By randomly selecting the same number of genes as Gene set #2 ($N = 1,274$) from the
252 background genes, and after repeating it 100,000 times, we calculated the number of overlapped
253 genes between Gene Set #1 and the sample we selected each time (N_{Random}). Finally, we calculated
254 the empirically permuted P value using the following formula: $P = \frac{N_{Random} \geq N_{Observation}}{N_{Total}}$, and
255 empirical P value ≤ 0.05 is considered to be significant.

256

257 ***Drug-gene interaction analysis***

258 We conducted a drug-gene interaction analysis for identified genetics-risk genes by using
259 protein-chemical interactions in the context of STRING-based PPI networks [43] and STITCH-
260 based drug annotation information (v5.0, <http://stitch.embl.de/>) [44]. Only experimentally-
261 validated gene-drug interactions with ranked confidence score were selected for constructing a
262 drug-gene interaction network. To examine the potential therapeutic effects of highly-expressed
263 genes in each immune cell, we conducted an enrichment analysis of 43 druggable categories based
264 on the DGIdb database (https://www.dgidb.org/druggable_gene_categories). Additionally, we
265 collected 1,263 human druggable proteins, which are therapeutic targets of clinical stage or
266 approved drugs, from a previous study [26]. Among them, 704 proteins are targets for potential
267 COVID-19-relevant drugs based on registers of clinical trials for COVID-19, approved

268 immunomodulatory/anticoagulant drugs, or have biological functions associated with SARS-CoV-
269 2 infection (Supplemental Table S11).

270

271 *Integrated analysis of GWAS summary statistics and scRNA-seq data*

272 To identify genetically regulatory-related peripheral immune cells for severe COVID-19, we
273 implemented the RolyPoly algorithm [45] to incorporate GWAS summary statistics with scRNA-
274 seq data. Let $g(i)$ stands for the gene associated with SNP i , $S_j = \{i : g(i) = j\}$ be the SNP set with
275 multiple SNPs associated with the gene j , and β_{S_j} be a GWAS-based effect-size vector of S_j with
276 a *priori* assumption that $\beta_{S_j} \sim \text{MVN}(\mathbf{0}, \sigma_j^2 \mathbf{I}_{|S_j|})$. Following the *priori*, RolyPoly gives a polygenic
277 linear model for β_{S_j} :

$$278 \quad \sigma_j^2 = \gamma_0 + \sum_{i=1}^N \gamma_i \alpha_{ji}$$

279 where γ_0 is an intercept term, $\alpha_{ji} (i=1,2,\dots,N)$ are annotations such as cell-type-specific gene
280 expression, and γ_i are annotation coefficients for α_{ji} . To fit the observed and expected sum
281 squared SNP effect sizes related to each gene by using the method-of-moments estimators,
282 RolyPoly estimates γ_i by the following equation:

$$283 \quad E\left(\sum_{i \in S_j} \hat{\beta}_i^2\right) = \sigma_j^2 \text{Tr}(\mathbf{R}_{S_j}^2) + |S_j| \sigma_e^2 n^{-1}$$

284 where \mathbf{R}_{S_j} is the LD matrix of S_j and Tr represents the trace of a matrix. Finally, RolyPoly applies
285 the block bootstrap method with 1,000 iterations to estimate standard errors $\hat{\sigma}_{\gamma_i}$ for calculating a t -
286 statistic and corresponding P values. The PLINK (v1.90) [46] was used to calculate the LD between
287 SNPs within the 1 Mb window based on the 1,000 Genome Project European Phase 3 panel [33].
288 We restricted the analysis to SNPs in the autosomes, and any SNPs with $\text{MAF} \leq 5\%$ were excluded.

289 The major histocompatibility complex region (Chr6: 25-35 Mbp) was also excluded due to the
290 extensive LD in this region.

291

292 ***Defining cell state scores***

293 We leveraged cell state scores to assess the immunological degree of each immune cell type
294 expressed a pre-curated expression gene set [11, 14, 29]. The cell state scores (CTS) were calculated
295 based on the average expression of genes from the pre-curated gene set in the respective cell with
296 the following formula: $CTS_k(m) = \text{average}(\text{RE}(GS_k, m)) - \text{average}(\text{RE}(GS_n, m))$, where GS_k is a
297 pre-defined gene set k in a given cell m , and GS_n is a control gene set that was randomly chosen on
298 the basis of aggregate expression levels bins, which obtain a comparable distribution of expression
299 levels and over size to that of the pre-curated gene set. RE represents the relative expression of GS_k
300 or GS_n . The *AddModuleScore* function in Seurat [30] was applied to calculate the CTS with default
301 parameters. We used the inflammatory and cytokine genes (N = 324 genes, Supplemental Table
302 S10), cytokine-cytokine receptor interactions (N = 294 genes), chemokine signaling pathway (N =
303 189 genes), T cell activation (GO: 0042110), response to interferon alpha (GO: 0035455), response
304 to interferon beta (GO: 0035456), leukocyte migration (GO: 0050900), 5 well-defined proliferating
305 markers (*MKI67*, *TYMS*, *NKG7*, *IL7R*, and *CCR7*), 6 well-defined exhaustion markers (*LAG3*,
306 *TIGIT*, *PDCD1*, *CTLA4*, *HAVCR2*, and *TOX*), and 12 cytotoxicity-associated genes (*PRF1*, *IFNG*,
307 *GNLY*, *NKG7*, *GZMB*, *GZMA*, *GZMH*, *KLRK1*, *KLRB1*, *KLRD1*, *CTSW*, and *CST7*) to define
308 inflammatory cytokine, chemokine, T cell activation, IFN- α/β response, migration, proliferation,
309 exhaustion, and cytotoxicity score, respectively.

310

311 ***Cell-to-cell interaction analysis***

312 To identify potential cellular interactions of $CCR1^+$ CD16⁺ monocytes and $CXCR6^+$ memory
313 CD8⁺T cells with other immune cells, we utilized the CellChat R package [47] for inferring the

314 predicted cell-to-cell communications based on two normalized scRNA-seq datasets (dataset #1 of
315 PBMC and dataset #4 of BALF). CellChat algorithm could examine the significance of ligand-
316 receptor interactions between two cell types depending on the expression of important factors,
317 including stimulatory and inhibitory membrane-bound co-receptors, soluble agonists and
318 antagonists. The communication probability of a signaling pathway was derived from the sum of
319 probabilities of their ligand-receptor interactions. We only concentrated on the ligand-receptor
320 interactions that significantly associated with severe COVID-19 compared with normal control.

322 *Statistical analysis*

323 The Wilcoxon sum-rank test was used to assess DEGs in mild, moderate, and severe COVID-
324 19 group compared with normal control. The Mann-Kendall trend analysis was applied to evaluate
325 the significance of cell state cells with elevated severities of COVID-19. Pathway- and disease-
326 based enrichment analyses used the hypergeometric test to identify remarkable biological pathways
327 and disease-terms. The Pearson correlation analysis was used to calculate the correlation coefficient
328 of highly-expressed genes in $CCRI^+$ CD16+monocytes between moderate and severe patients. The
329 paired Student's t test was used to calculate the significance of ligand/receptor interactions of
330 $CCRI^+$ CD16+monocytes and $CXCR6^+$ memory CD8+T cells with other immune cells between
331 normal control and severe COVID-19.

333 **Results**

334 *The computational framework for integrating single-cell transcriptomes and GWAS on COVID-* 335 *19*

336 As shown in Figure 1, we devised a computational framework to parse the host genetics-
337 modulated immune cell subpopulations implicated in severe COVID-19. It included three main
338 parts: 1) integrative analysis that combined GWAS summary statistics with scRNA-seq data to

339 genetically map single-cell landscape for severe COVID-19 (Figure 1A); 2) identifying genetics-
340 risk genes, pathways, and immune cell subpopulations that contributed to cytokine storms among
341 severe patients (Figure 1B); and 3) uncovering the cellular interactions of genetics-modulated
342 immune cell subsets, as well as their functions with cells in lung tissues (Figure 1C).

343

344 ***Identification of immune cell types associated with severe COVID-19***

345 To parse the host genetics-influenced immune responses at single cellular level in PBMCs for
346 severe COVID-19, we subjected three independent scRNA-seq datasets with 563,856 cells to
347 UMAP based on highly variable genes using the Seurat (See Methods) [30]. There was
348 identification of 13 distinct clusters unbiased by patients with different severities (Supplemental
349 Figure S1). We leveraged well-known marker genes to assign these clusters to 13 distinct cell types,
350 including mature B cells, megakaryocytes, naïve B cells, CD34+progenitors, dendritic cells, natural
351 killer (NK) cells, CD14+monocytes, CD16+monocytes, memory CD4+T cells, naïve CD4+T cells,
352 naïve CD8+T cells, memory CD8+T cells, and effector CD8+T cells (Supplemental Figures S2-
353 S3).

354 While performing the hierarchical clustering analysis on the scRNA-seq profiles, we
355 discovered that cell types were the primary determinants of their clustering, followed by disease
356 severities, indicating both COVID-19 pathology and immune cell types might have crucial roles in
357 altered patterns of immune transcriptome instead of technical artifacts (Supplemental Figure S4).
358 As a vital feature for reflecting the alterations of immune responses, we examined the relative
359 proportions of peripheral immune cells across different COVID-19 groups in comparison with
360 normal group. The proportions of CD14+monocytes, megakaryocytes, and CD34+progenitors were
361 significantly elevated in moderate and severe patients, whereas the proportions of
362 CD16+monocytes, effector CD8+ T cells, memory CD8+T cells, memory CD4+T cells, naïve

363 CD4+T cells, and NK cells were significantly decreased with the increased severities
364 (Supplemental Figure S5).

365

366 ***Identification of genetic risk loci associated with severe COVID-19***

367 Through performing a meta-analysis of 21 independent GWAS studies from the COVID-19
368 Host Genetic Consortium, eight genomic loci were identified to be associated with hospitalized
369 COVID-19 at a genome-wide significant level, including 1p22.2 (rs2166172, $P = 2.74 \times 10^{-8}$),
370 3p21.31 (rs35081325, $P = 3.32 \times 10^{-58}$, and rs33998492, $P = 3.59 \times 10^{-14}$), 6p21.33 (rs143334143, P
371 $= 1.28 \times 10^{-10}$), 7p11.2 (rs622568, $P = 2.57 \times 10^{-8}$), 9q34.2 (rs505922, $P = 2.24 \times 10^{-9}$), 12q24.13
372 (rs2269899, $P = 3.24 \times 10^{-8}$), 19p13.3 (rs2109069, $P = 6.4 \times 10^{-13}$), and 21q22.11 (rs13050728, P
373 $= 1.91 \times 10^{-11}$) (Figure 2A, Supplemental Table S3, Figure S6, and Materials S2). Among these eight
374 loci, three loci, 1p22.2, 6p21.33 and 7p11.2, were newly identified. It should be noted that there
375 were two independent genetic association signals (Index SNPs: rs35081325 and rs33998492) in the
376 3p21.31 locus for severe COVID-19 (Figure 2B and Supplemental Figure S7A-C). Using the
377 Variant2Gene (V2G) algorithm [48], we prioritized *CXCR6* as a candidate causal gene for
378 rs35081325 and causal gene *CCR1* for rs33998492 (Supplemental Method S1).

379 Furthermore, the index SNP of rs505922 ($P = 2.24 \times 10^{-9}$) in the 9q34.2 locus is highly LD with
380 the reported SNP of rs657152 ($R^2 = 0.874$) [27] and rs8176719 ($R^2 = 0.876$) [25]. Based on the top-
381 ranked V2G score for rs505922, we prioritized *ABO* as a potential causal gene contributing
382 susceptibility to severe COVID-19. By performing a MAGMA gene-level association analysis, we
383 observed that 25 genes including *CXCR6*, *CCR1*, *IFNAR2*, *IL10RB*, and *OAS1* were significantly
384 associated with severe COVID-19 ($FDR < 0.05$, Supplemental Figure S8 and Table S4). GWAS-
385 based pathway enrichment analysis revealed that 19 biological pathways, including cytokine-
386 cytokine receptor interaction, influenza A, and TNF signaling, were significantly associated with
387 hospitalized COVID-19 (Supplemental Figure S9 and Table S5).

388

389 ***Integrative analysis of GWAS on severe COVID-19 with GTEx eQTL data***

390 To obtain combined signals from multiple tissues [49], we leveraged S-MultiXcan to meta-
391 analyze the tissue-specific associations from 49 tissues in GTEx (see Methods), which showed that
392 the genetically predicted expressions of 16 genes were significantly associated with severe COVID-
393 19 (FDR < 0.05, Figure 2C and Supplemental Table S6). Of note, 14 of 16 genes (87.5%) were
394 identified to be significant in MAGMA analysis (Supplemental Figure S10A-B). Through
395 conducting S-PrediXcan analysis of blood and lung tissues that were linked with SARS-CoV-2
396 infection, we found eight genes whose genetically-regulated expression were significantly
397 associated with severe COVID-19 (FDR < 0.05, Supplemental Table S7). Using *in silico*
398 permutation analysis, we further observed that there existed a high consistence among results from
399 MAGMA, S-PrediXcan, and S-MultiXcan analyses ($P < 1.0 \times 10^{-5}$, Supplemental Figure S11A-C).
400 The aforementioned multiple genomic analyses identified 34 risk genes that showed supportive
401 evidence of involvement in the etiology of COVID-19 (Supplemental Figure S12A-B).

402

403 ***Functional characterization of 34 risk genes for severe COVID-19***

404 The result of a network-based enrichment analysis suggested that 22 of 34 risk genes were
405 significantly enriched in a PPI subnetwork ($P = 2.85 \times 10^{-13}$, Figure 2D), which is consistent with
406 the consensus that disease-related genes are more densely connected [50, 51]. To functionally
407 characterize the drug targets of these genes, we conducted a drug-gene interaction analysis and
408 identified 11 genes including *CCR1*, *IFNAR2*, *IL10RB*, and *OAS1* were targeted by at least one
409 known drug (Figure 2D and Supplemental Figure S14), of which some genes including *CCR1*,
410 *IFNAR2*, and *IL10RB* have been reported to be drug targets for treating severe COVID-19 patients
411 [25, 26]. Furthermore, these 34 genes were significantly enriched in a functional module consisting
412 of 10 biological pathways (Figure 2E, Supplemental Table S8 and Figure S13), among which two

413 top-ranked ones being cytokine-cytokine receptor interaction and chemokine signaling pathway
414 (FDR < 0.05). Most of these enriched pathways have been reported to be implicated in COVID-19
415 [25, 52, 53].

416 Based on the expression profile of dataset #1, we conducted a hierarchical clustering analysis
417 of these identified risk genes on COVID-19 severity, and found that these risk genes predisposed
418 be highly-expressed in severe patients compared to normal group (Permuted P = 0.023, Figure 2F-
419 G). Consistently, the number of significant enriched pathways were elevated with increased
420 severities (Figure 2H). Genes in both cytokine-cytokine receptor interaction and chemokine
421 signaling pathways showed significantly high expressions in the early phase of SARS-CoV-2
422 infection (Figure 2H), suggesting that these two pathways could play critical roles in the initiation
423 of COVID-19.

424

425 ***Genetics-influenced peripheral immune cell types for severe COVID-19***

426 To identify genome-wide genetics-influenced immune cells for severe COVID-19, we first
427 leveraged a regression-based polygenic model to integrate GWAS summary data on severe
428 COVID-19 with single-cell transcriptomic profiles (dataset #1) according to different COVID-19
429 severities (See methods). We found that CD16+monocytes were significantly associated with three
430 phases of COVID-19, mature B cells showed remarkable associations with mild COVID-19,
431 megakaryocytes were significantly associated with moderate and severe COVID-19, and memory
432 CD8+T cells showed significant associations with severe COVID-19 (simulated P < 0.05, Figure
433 3A). Further, we used a generalized linear regression model to validate these severe COVID-19-
434 associated cell types by conditioning on the 10% most specific genes for each type, and consistently
435 found that CD16+monocytes and megakaryocytes showed notable associations with severe
436 COVID-19 (P < 0.05, Supplemental Method S2). These results indicated that CD16+monocytes,

437 megakaryocytes, and memory CD8+T cells were more vulnerable to the influence of genetic
438 components on severe-stage patients.

439 Based on the specificity algorithm used in MAGMA, we noticed that the top specific cell type
440 of *CCR1* was CD16+monocytes, *CXCR6* was most specifically expressed in memory CD8+T cells,
441 and *ABO* was specific to megakaryocytes (Supplemental Figure S15A), recalling that *CXCR6*,
442 *CCR1* and *ABO* were prioritized to be candidate causal genes for severe COVID-19 based on the
443 V2G score in above genetics-based analysis. Compared with other cell types, *CCR1* was primarily
444 expressed in CD16+monocytes (24.77%), *CXCR6* was mainly expressed in memory CD8+T cells
445 (40.29%), and the *ABO*-expressed cells were highly specific to megakaryocytes (54.63%)
446 (Supplemental Figure S15B and Table S9). To gather additional empirical support, we analyzed the
447 combined dataset of both datasets #2 and #3 as a validation and found *CCR1*, *CXCR6*, and *ABO*
448 showed a consistent specificity in the three cell types (Supplemental Figure S16).

449 Given that the primary goal of current study was to characterize genetics-influenced peripheral
450 immune cell types for severe COVID-19, the majority of our subsequent detailed analyses would
451 be concentrated on three immune cell subpopulations: *CCR1*⁺ CD16+monocytes, *ABO*⁺
452 megakaryocytes, and *CXCR6*⁺ memory CD8+T cells (Figure 3B).

453

454 ***CCR1*⁺ CD16+monocytes and *ABO*⁺ megakaryocytes contributing higher risk to cytokine storm**

455 The accumulating lines of evidence [29, 54] have suggested that subsets of monocytes and
456 megakaryocytes might be the major resources of inflammatory storm. We sought to examine
457 whether *CCR1*⁺ CD16+monocytes and *ABO*⁺ megakaryocytes play more important roles in
458 cytokine storm among severe patients. As for *CCR1*⁺ CD16+monocytes, we found that the
459 inflammatory cytokine score was significantly higher than that of *CCR1*⁻ CD16+monocytes (P =
460 2.5×10^{-7} , Figure 4A). Consistently, the combined score of both cytokine-cytokine receptor
461 interaction and chemokine signaling pathway was prominently higher in *CCR1*⁺ CD16+monocytes

462 ($P < 2.2 \times 10^{-16}$, Supplemental Figure 17A). Compared with *CCR1*⁻ CD16⁺ monocytes, there were
463 351 significantly highly-expressed genes in *CCR1*⁺ CD16⁺ monocytes, such as inflammatory and
464 cytokine genes of *IL1B*, *IL27*, *CXCL10*, *CXCL8*, *CD14*, and *OSM* (FDR < 0.05, Figure 4B and
465 Supplemental Table S11), which have been documented to be associated with the inflammatory
466 response and chemotaxis of immune cells among COVID-19 patients [10, 15, 55, 56]. Functionally,
467 19 KEGG pathways were significantly overrepresented by the 351 highly-expressed genes (FDR <
468 0.05, Figure 4C and Supplemental Table S12), including cytokine-cytokine receptor interaction and
469 chemokine signaling pathway, reminiscing that most of them were identified in above genetics-
470 based pathway analysis. Additionally, these highly-expressed genes among *CCR1*⁺
471 CD16⁺ monocytes have a remarkably higher proportion of druggable genes and COVID-19-
472 associated druggable genes ($P \leq 0.01$, Supplemental Figure S17 and Table S13).

473 The cell percentage of *CCR1*⁺ CD16⁺ monocytes showed a notable elevation among moderate
474 and severe patients compared with normal controls ($P < 0.001$), with no significant difference
475 between mild patients and normal controls ($P = 0.1$, Figure 4D). Furthermore, the inflammatory
476 cytokine scores among *CCR1*⁺ CD16⁺ monocytes were significantly elevated with increased
477 severities (Trend $P = 0.0013$, Figure 4E). In comparison with normal controls, mild, moderate, and
478 severe patients displayed significantly up-regulated expressions (up-DEGs) with 14, 169, and 190
479 genes respectively (FDR < 0.05, Figure 4F and Supplemental Figure S17D). Notably, there existed
480 a high correlation between up-DEGs of moderate and severe patients ($r = 0.937$, $P < 2.2 \times 10^{-16}$;
481 Figure 4G), such as *S100A8*, *S100A9*, and *IFITM1* (Figure 4H-4J), indicating a similar expression
482 pattern between moderate and severe patients. Accumulating release of massive amounts of
483 calprotectin (*S100A8/S100A9*) in monocytes contributes to inflammatory response among severe
484 COVID-19 patients [10, 16, 29].

485 Furthermore, these 190 up-DEGs were significantly enriched in disease-terms associated with
486 viral infection and inflammation and 17 functional GO-terms (FDR < 0.05, Figure 4K,

487 Supplemental Figure S17E and Tables S14-S15), including interferon alpha/beta signaling and
488 interferon gamma signaling. These interferon-related genes including *IRF3*, *IRF2*, *IFI6*, *IFITM1*,
489 *ISG15*, and *ICAM1* may induce autoinflammatory and autoimmune conditions contributing to the
490 innate immune cells against SARS-CoV-2 infection [57, 58]. Of note, a high proportion of 63.68%
491 among 190 up-DEGs such as *CXCL8*, *IFITM1*, *S100A8*, and *S100A9* were annotated into 15
492 potential druggable gene categories (Supplemental Figure S17F-L and Table S16). These results
493 indicated that interferon-related genes among *CCR1*⁺ CD16⁺ monocytes have instrumental effects
494 in exacerbating inflammation among severe patients.

495 In addition, we found that *ABO*⁺ megakaryocytes had a significantly higher inflammatory
496 cytokine score than that in *ABO*⁻ cells ($P < 0.001$, Supplemental Figure S18A-B). Compared with
497 *ABO*⁻ megakaryocytes, 424 genes were significantly highly-expressed in *ABO*⁺ megakaryocytes
498 (FDR < 0.05 , Supplemental Figure S18C and Table S17). These 424 highly-expressed genes were
499 significantly enriched in systemic lupus erythematosus, alcoholism, and platelet activation (FDR $<$
500 0.05 , Supplemental Figure S18D and Table S18). Similar to *CCR1*⁺ CD16⁺ monocytes, the cell
501 percentage of *ABO*⁺ megakaryocytes was significantly elevated among moderate and severe
502 patients ($P < 0.01$, Supplemental Figure S18E). Among *ABO*⁺ megakaryocytes, 20 and 35 up-DEGs
503 were notably associated with moderate and severe patients, respectively (FDR < 0.05 , Supplemental
504 Figure S18F-G). There was a highly overlapped rate of these up-DEGs between moderate and
505 severe COVID-19 groups, including *ACPI1*, *S100A8*, and *A100A9* ($18/20 = 90\%$, Supplemental
506 Figure S18F-N). These 35 up-DEGs were annotated to 12 druggable gene categories and
507 significantly enriched in several disease terms (Supplemental Figure S18H and Tables S19-S20),
508 such as shock and thrombocytopenia, which were reported to be associated with COVID-19 [59].
509 Overall, these results suggest that both *CCR1*⁺ CD16⁺ monocytes and *ABO*⁺ megakaryocytes
510 contribute higher risk to inflammatory storm among severe patients.

511

512 *CXCR6⁺ memory CD8⁺T cells convey risk to severe COVID-19*

513 Earlier studies [10, 60] have indicated that polyfunctional T cells play important roles in
514 dominating the anti-viral infection immune response and can release a substantially higher amount
515 of multiple distinct cytokines and chemokines in comparison to other T cells. It is plausible to infer
516 that there exist subsets of memory CD8⁺T cells predisposing to be multi-functional for against
517 SARS-CoV-2 infection. We calculated several immunological features to evaluate whether
518 *CXCR6⁺* memory CD8⁺T cells have a higher polyfunctionality than *CXCR6⁻* memory CD8⁺T cells.
519 Compared with *CXCR6⁻* memory CD8⁺T cells, we found that scores of cytokine, chemokine, IFN-
520 α/β response, T cell activation, proliferation, and migration were significantly higher among
521 *CXCR6⁺* memory CD8⁺T cells ($P < 0.05$, Figure 5A-D and Supplemental Figure S19A-C). There
522 were 158 highly-expressed genes among *CXCR6⁺* memory CD8⁺T cells in comparison with
523 *CXCR6⁻* cells ($FDR < 0.05$, Figure 5E). These highly-expressed genes were significantly enriched
524 in two biological pathways of cytokine-cytokine receptor interaction and inflammatory bowel (FDR
525 < 0.05 , Supplemental Figure S19D and Table S21). The chemokine signaling pathway showed a
526 suggestive enrichment ($P < 0.05$). These highly-expressed genes contained numerous pro-
527 inflammatory cytokine and chemokine genes, such as *CCR1*, *CCR2*, *CCR5*, *CCR6*, *CCL3L1*,
528 *IFNGR1*, *IL18R1*, *IL23R*, *MYC*, and *TNFSF14*, which may be associated with the activation of
529 memory CD8⁺T cells.

530 Furthermore, the cell proportion of *CXCR6⁺* memory CD8⁺T cells was significantly higher
531 among both mild and moderate COVID-19 than that among normal group ($P < 0.05$), whereas the
532 cell proportion of *CXCR6⁺* memory CD8⁺T cells among severe COVID-19 was remarkably lower
533 than that among normal group ($P = 0.012$, Figure 5F). Consistently, we found that the scores of
534 chemokine, T cell activation, and migration were increased with the increasing patient severities
535 among *CXCR6⁺* memory CD8⁺T cells (Trend $P < 0.05$, Figure 5G-I), and that lower cytotoxicity
536 score and exhaustion score were observed among moderate-to-severe patients (Trend $P < 0.05$,

537 Supplemental Figure S19E-F). Additionally, we found 44, 42, and 53 up-DEGs that were notably
538 associated with mild, moderate, and severe COVID-19, and there were six significant common
539 genes across three phases of COVID-19, including *TCF7*, *GZMH*, *RAB5IF*, *CCND2*, *BIRC6*, and
540 *NDUFAF3* (Figure 5J-K and Supplemental Figure S19G-N). The gene of *TCF7* was an essential
541 factor in memory CD8+T cell differentiation [61], and *GZMH* was reported to mediate antiviral
542 activity through direct cleavage of viral substrates [62]. These 108 up-DEGs were found to be
543 significantly enriched in 22 functional GO-terms, including Fc-gamma receptor signaling pathway,
544 regulation of leukocyte differentiation, and activation of immune response (Figure 5L-M and
545 Supplemental Table S22). Overall, these results indicated that *CXCR6*⁺ memory CD8+T cells have
546 an enhanced propensity to be multi-functional and activated T cells involved in severe COVID-19.

547

548 ***Elevated cellular interactions may enhance the resident to lung airway for COVID-19***

549 To gain refined insights into *CCR1*⁺ CD16+monocytes and *CXCR6*⁺ memory CD8+T cells, we
550 examined the cellular interactions among cell populations in PBMCs and BALFs according to the
551 COVID-19 disease status using the CellChat algorithm [47]. For *CCR1*⁺ CD16+monocytes in
552 PBMCs, we found a notable increase in cell-to-cell interactions with other immune cells among
553 severe patients than that in normal controls ($P < 0.05$, Figure 6A and Supplemental Figure S20).
554 There was no statistical difference in cellular communications of *CCR1*⁻ CD16+monocytes with
555 other cells between normal and COVID-19 patients ($P > 0.05$, Figure 6B). Compared with normal
556 controls, *CCR1*⁺ CD16+monocytes showed elevated interactions with megakaryocytes, memory
557 CD8+T cells, NK, effector CD8+T cells, and CD14+monocytes among severe patients
558 (Supplemental Figure S20). There were 14 ligand-receptor interactions observed to be remarkably
559 dominated among severe patients (Figure 6C), including *ANXA1-FPR1*, *ITGB2-ICAM2/CD226*,
560 *LGALS9-CD44*, *SELPLG-SELL/SELP*, *APP-CD74*, and *THBS1-CD36/CD47*.

561 With regard to *CXCR6*⁺ memory CD8⁺T cells in PBMCs, the predicted cell-to-cell interactions
562 showed a prominent elevation with increased severities of COVID-19 ($P < 0.05$, Figure 6D).
563 Similar to *CCR1*⁻ CD16⁺monocytes, we observed no obvious difference of cellular interactions
564 between normal controls and COVID-19 patients among *CXCR6*⁻ memory CD8⁺T cells ($P > 0.05$,
565 Figure 6E). Compared with healthy individuals, *CXCR6*⁺ memory CD8⁺T cells demonstrated
566 higher cellular communications with CD14⁺monocytes, CD34⁺progenitors, dendritic cells,
567 effector CD8⁺T cells, naïve CD8⁺T cells, memory CD4⁺T cell, naïve CD4⁺T cells, NK, and
568 megakaryocytes among severe patients (Supplemental Figure S20). There were 20 elevated cellular
569 interactions of *CXCR6*⁺ memory CD8⁺T cells with other immune cells among severe patients,
570 including *ADGRE5-CD55*, *ANXA1-FPR1*, *CCL3/CCL5-CCR1*, *CD99-CD99/PILRA*, *ICAM2-*
571 *(ITGAL+ITGB2)*, and *ITGB2-ICAM2/CD226* (Figure 6F). These cell adhesion molecules (*ANXA1*
572 and *ICMA2*), cytokine binding and receptor activity genes (*CD44*, *CD36*, *CD74*, *CXCR4*, and
573 *THBS1*), and inflammatory genes (*FPR1* and *SELL*) have been reported to be associated with
574 COVID-19 [16, 55, 63, 64].

575 Among BALF cells, we also observed a remarkable increase in cellular interactions of *CCR1*⁺
576 CD16⁺monocytes and *CXCR6*⁺ memory CD8⁺T cells comparing to their corresponding negative
577 cells ($P < 0.001$, Figure 6G-J and Supplemental Figure S21A). For example, enhanced ligand-
578 receptor axes of *SELPLG-SELL*, *CCL5-CCR1*, *FNI-(ITGA4+ITGB1)*, *CD99-CD99*, and *APP-*
579 *CD74* among *CCR1*⁺ CD16⁺monocytes (Figure 6H), as well as *CXCL16-CXCR6*, *TNFSF14-*
580 *TNFRSF14*, *ITGB2-CD226*, *CLEC2B/CLEC2C-KLRB1*, and *CCL3/CCL4-CCR5* among *CXCR6*⁺
581 memory CD8⁺T cells (Figure 6J). Notably, there was a 60% increase in cellular interactions
582 between *CCR1*⁺ CD16⁺monocytes and epithelial cells compared with that of *CCR1*⁻
583 CD16⁺monocytes (Supplemental Figure S21B). We also found a 33.33% increase in the
584 interactions between *CXCR6*⁺ memory CD8⁺T cells and epithelial cells compared with that of
585 *CXCR6*⁻ memory CD8⁺T cells (Supplemental Figure S21C), such as enhanced ligand-receptor

586 interactions including *TNF-TNFRSF1A*, *CXCL16-CXCR6*, and *CCL3-CCR5*. Previous studies [65,
587 66] have reported that the *CXCL16-CXCR6* axis modulates the localization of tissue-resident
588 memory CD8+T cells to the lung airway. Overall, these results suggest that the increased cellular
589 interactions with epithelial cells probably enhance the resident to the lung airway for against SARS-
590 CoV-2 infection.

591

592

Discussion

593 By using large-scale genetics data, we identified eight genomic loci including three novel loci
594 (e.g., 1p22.2, 6p21.33, and 7p11.2) that were significantly associated with severe COVID-19. Other
595 five loci including 3p21.31, 9q34.2, 12q24.13, 19p13.3, and 21q22.11 have been reported to be
596 involved in COVID-19 risk in previous studies [23-28]. Notably, we prioritized 34 risk genes,
597 including potential causal genes of *CXCR6*, *CCR1*, and *ABO*, to be associated with severe COVID-
598 19. The CXC motif chemokine receptor 6 (*CXCR6*), which is a G protein-coupled receptor with
599 seven transmembrane domains, regulates the partitioning of resident memory T cells by recruiting
600 lung tissue-resident memory CD8+T cells to airways [65]. *CCR1* gene encodes the CC motif
601 chemokine receptor 1 (*CCR1*) belonging to a member of the beta chemokine receptor family.
602 Several previous GWASs have reported genetic variants in *CCR1* are associated with COVID-19
603 susceptibility at a genome-wide significant level [25, 27]. For the *ABO* gene, it encodes protein
604 relevant to the ABO blood group system. Both genetic and non-genetic studies [25, 27, 67] have
605 showed the involvement of *ABO* gene in COVID-19 susceptibility, while the *ABO* gene encodes
606 protein that is relevant to the ABO blood group system, and it was also notably associated with
607 several thrombotic and coagulation-related traits including deep vein thrombosis and pulmonary
608 heart disease, which have been reported to be risk factors and sequelae to severe COVID-19 [68,
609 69].

610 Understanding the immune responses of monocytes and memory T cells is fundamental to the
611 rational design of innovative and effective strategies to develop better vaccines [70, 71], and
612 contributes to reveal the pathogenesis of severe COVID-19 [29]. Our current analyses reveal that
613 host genetic determinants have a prominent influence on the immune responses of
614 CD16+monocytes, megakaryocytes, and memory CD8+T cells to severe COVID-19. Previous
615 studies [11, 29, 54] showed that the influence caused by monocytes and megakaryocytes in
616 inflammatory storms is noteworthy among severe COVID-19 patients. We found that *CCR1*⁺
617 CD16+monocytes and *ABO*⁺ megakaryocytes showed a significantly increased propensity to cause
618 inflammatory storms among severe patients. The observations suggest highly-expressed interferon-
619 related genes, including *S100A8*, *S100A9*, *S100A12*, *CD14*, *CXCL8*, *IGSF6*, *IRF3*, *IFI6*, *IFITM1*,
620 and *IFITM3* among the two cell subsets contribute to exacerbate inflammation among severe
621 patients. The inflammatory mediator of EN-RAGE encoded by *S100A12* was significantly
622 correlated with COVID-19 [21], and *S100A8*, *S100A9*, *IRF3*, *IFI6*, *IFITM1*, and *IFITM3* have been
623 reported to elicit autoinflammatory and autoimmune conditions in response to SARS-CoV-2
624 infection [10, 16, 29, 57, 58]. Double positive CD14+CD16+monocytes reported as tissue-
625 infiltrative cells have a higher potency of antigen presentation and highly-expressed
626 proinflammatory cytokines [72, 73]. Additionally, interferons are the mediators in several canonical
627 host antiviral signaling to activate the expression of numerous required molecules of the early
628 response to viral infection [74], and impaired type I interferon activity play important roles in severe
629 COVID-19 [58]. Our findings described above suggest that *CCR1*⁺ CD16+monocytes and *ABO*⁺
630 megakaryocytes as a functional subset of myeloid cells convey higher risks to severe COVID-19.

631 Memory CD8+T cells could elicit improved immunological features that are critical in host
632 protection from viral infectious [71]. After influenza virus infections, memory CD8+T cells reside
633 in the lung for a couple of months and these resident memory T cells are necessary for effective
634 immunity against secondary infection [75]. Among severe COVID-19 patients, we found that

635 *CXCR6*⁺ memory CD8⁺T cells undertook several improved immunological features, including
636 higher scores of cytokine, chemokine, T cell activation, proliferation, and migration, which
637 suggests *CXCR6*⁺ memory CD8⁺T cells potentially contribute to the protection of SARS-CoV-2
638 infection. Among these positive *CXCR6*⁺ cells, numerous highly-expressed cytokine and
639 chemokine genes, including *CCR1*, *CCR2*, *IFNGR1*, and *MYC*, may work on activating memory T
640 cells. Earlier evidence indicated that *MYC* was rapidly but temporally induced during the early
641 stage of T cell activation [76]. The *CCR1* plays a pivotal role in the recruitment of effector immune
642 cells to the site of inflammation, and the pharmacologic inhibition of this gene may suppress
643 immune hyper-activation in severe COVID-19 [15]. Memory CD8⁺T cells obtained the capability
644 of transforming to effector cells by sensing inflammation from monocytes [71]. Thus, inflammatory
645 *CCR1*⁺ CD16⁺monocytes among severe COVID-19 patients potentially accelerate the activation
646 of memory CD8⁺T cells.

647 Additionally, we observed a prominent decrease of the cell proportion of *CXCR6*⁺ memory
648 CD8⁺T cells among severe patients. This decrease in peripheral blood among severe patients is
649 probably due to efflux to the site of viral infected lung tissue in answer to ongoing tissue damage.
650 Earlier studies [29, 77] have reported that functional CD8⁺T cell subsets manifest a notable
651 decrease in the peripheral blood of severe COVID-19 patients. Epithelium is the most vulnerable
652 tissue to be attacked by viral or microbial infection, thus the presence of resident memory CD8⁺T
653 cells are imperative for defending the debilitating infections for hosts [75]. In the current study, we
654 found an obvious increase in cellular interactions of *CXCR6*⁺ memory CD8⁺T cells with
655 epitheliums. Enhanced ligand-receptor interactions including *TNF-TNFSFRSF1A*, *CXCL16*-
656 *CXCR6*, and *CCL3-CCR5* may contribute to the lung-residence of memory CD8⁺T cells. Previous
657 evidence demonstrated a major role for *CXCL16-CXCR6* interactions in regulating the resident of
658 virus-specific memory CD8⁺T cells [65, 66]. An earlier study showed a stronger interactions
659 between epithelial and immune cells among severe COVID-19 cases than that among moderate

660 cases [15]. We demonstrated that *CXCR6*⁺ memory CD8⁺T cells mounted highly effective immune
661 responses to against COVID-19, highlighting the remarkable biological plasticity in subsets of
662 memory CD8⁺T cells differentiation.

663 The power of this study is limited by the lack of matched genetic data and scRNA-seq data in
664 each sample for uncovering the genetic effects on immune cells for severe COVID-19. To reduce
665 the influence of this limitation, we adopted a widely-used approach by integrating a large-scale
666 GWAS summary statistics with enormous amount of single cell sequencing data, as referenced in
667 previous studies [45, 78]. Based on our findings suggesting that host genetic components exert
668 regulatory effects on immunological dysregulations for SRAS-CoV-2 infection, more studies are
669 warranted for exploring the genetic modification of peripheral T cells to defend against lethal severe
670 COVID-19.

671

672 **Conclusions**

673 In sum, we provide comprehensive insights that host genetic determinants are fundamental in
674 influencing the peripheral immune responses to severe COVID-19. Both *CCR1*⁺ CD16⁺monocytes
675 and *ABO*⁺ megakaryocytes contribute higher risk to the inflammatory storms among severe patients.
676 *CXCR6*⁺ memory CD8⁺T cells exhibit a notable polyfunctionality of several improved
677 immunologic features implicated in the etiology of severe COVID-19. Further experiments to parse
678 the molecular mechanism of these three cell subpopulations on severe COVID-19 patients are
679 crucial for promoting personalized protective immunity.

680

681 **Abbreviations**

682 COVID-19: coronavirus disease 2019; SARS-CoV-2: severe acute respiratory syndrome
683 coronavirus 2; GWAS: genome-wide association study; scRNA-seq: single cell RNA sequencing;
684 PBMCs: peripheral blood mononuclear cells; BALF: bronchoalveolar lavage fluid; eQTL:

685 expression quantitative trait loci; GEO: the Gene Expression Omnibus database; WHO: the World
686 Health Organization; SNP: single nucleotide polymorphism; OR: odds ratio; MAF: minor allele
687 frequency; QQ: quantile-quantile; MAGMA: Multi-marker Analysis of GenoMic Annotation; LD:
688 linkage disequilibrium; FDR: false discovery rate; KEGG: the Kyoto Encyclopedia of Genes and
689 Genomes; PPC: the Pearson correlation coefficient; MDS: multidimensional scaling; OTG: the
690 Open Target Genetics; PPI: protein-protein interaction; up-DEG: significantly up-regulated
691 expression gene associated with COVID-19.

692

693 **Declarations**

694 **Acknowledgments**

695 We appreciate Prof. Yang Jian from Westlake University for providing helpful suggestions, and
696 our appreciation also goes to all the authors from the COVID-19 Host Genetic Consortium who
697 have deposited and shared GWAS summary data on public databases and goes to the authors who
698 publicly released the scRNA-seq datasets on PBMC and BALF with distinct COVID-19 severities.

699

700 **Authors' contributions**

701 J.S., and Y.M. conceived and designed the study. Y.M., F.Q., C.D., J.L., Y.K.H., Y.R.Z., Y.X.,
702 Y.G.Z., and Y.H.Y. contributed to management of data collection. Y.M., F.Q., C.D., Y.K.H., and
703 J.L. conducted bioinformatics analysis and data interpretation. Y.M., J.S., Z.W. and J.Q. wrote the
704 manuscripts. All authors reviewed and approved the final manuscript.

705

706 **Funding**

707 This study was funded by the National Natural Science Foundation of China (61871294 to J.S.),
708 the Scientific Research Foundation for Talents of Wenzhou Medical University (KYQD20201001
709 to Y.M.), and Science Foundation of Zhejiang Province (LR19C060001 to J.S).

710

711 **Data and materials availability:**

712 All the GWAS summary statistics used in this study can be accessed in the official websites
713 (www.covid19hg.org/results). The GTEx eQTL data (version 8) were downloaded from Zenodo
714 repository (<https://zenodo.org/record/3518299#.Xv6Z6igzbg1>). Three scRNA-seq datasets were
715 downloaded from the GEO database (<https://www.ncbi.nlm.nih.gov/gds/?term=GSE149689> and
716 <https://www.ncbi.nlm.nih.gov/gds/?term=GSE150861>) and the ArrayExpress database
717 (<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-9357>). All analysis code in the
718 Methods is available in an online GitHub repository at
719 https://github.com/mayunlong89/COVID19_scRNA.

720

721 **Ethics approval and consent to participate**

722 Not applicable

723

724 **Consent for publication**

725 Not applicable

726

727 **Competing interests:**

728 The authors declare no competing interests.

729

730 **Figure Legends**

731 **Figure 1. The workflow for this integrative genomic analysis.** A) Combination of single cell
732 RNA sequencing data and GWAS summary statistics on severe COVID-19 based on two
733 independent methods. One method is regression-based polygenic model based on whole scRNA-
734 seq profiles, and another is generalized linear regression model based on top 10% most specific

735 genes for each cell type. B) An increase in genetics-risk genes and cytokines for severe COVID-19.
736 C) Cellular interaction analysis of genetics-influenced immune cell subsets with epithelial cells.
737
738 **Figure 2. Risk genes and pathways associated with hospitalized COVID-19 from meta-GWAS**
739 **summary data.** A) Manhattan plot and quantile-quantile (QQ) plot of meta-GWAS analysis
740 highlighting eight risk genetic loci for hospitalized COVID-19. The red horizontal line represents
741 the genome-wide significance threshold of $P < 5 \times 10^{-8}$. The genomic inflation factor $\lambda = 1.02$. B)
742 Nine index SNPs within eight genomic loci associated with hospitalized COVID-19. Left panel
743 shows the P value of each index SNP, and right panel shows the odds ratio with 95% confidence
744 interval. C) Circus plot showing the results of S-MultiXcan-based analysis. The inner ring
745 demonstrates the 22 autosomal chromosomes (Chr1-22). In the outer ring, a circular symbol
746 represents a specific gene and color marks the statistical significance of the gene for hospitalized
747 COVID-19 (Red marks $FDR < 0.05$, orange indicates $6.96 \times 10^{-5} \leq P < 0.001$, light blue marks 0.001
748 $\leq P \leq 0.05$, and dark blue indicates $P > 0.05$). D) PPI network of these 34 identified risk genes based
749 on the STRING database (v11.0, <https://string-db.org/>). Orange ring represents druggable genes
750 targeted by at least one known drug. E) Network module constructed by using the Jaccard distance
751 showing the connectivity of 10 significant pathways enriched by 34 risk genes. F) Heatmap
752 showing the results of hierarchical clustering analysis of 27 risk genes on COVID-19 severity.
753 Seven risk genes did not expressed in the dataset #1, and the expression level of each gene was
754 scaled. G) The proportion of highly-expressed genes among 27 risk genes in normal controls and
755 in the three phases of COVID-19 (mild, moderate, and severe patients). Using 10,000 times of
756 permutation analysis to calculate the significance of the observation (permuted $P = 0.023$). H) Plot
757 showing an increase of the significantly enriched pathways in the network module with elevated
758 COVID-19 severities. Orange color represents a significant enriched pathway ($FDR \leq 0.05$) and
759 gray color represents a non-significant enriched pathway ($FDR > 0.05$).

760

761 **Figure 3. Integrative analysis identifies genetic associations between peripheral immune cells**
762 **and severe COVID-19.** A) Bar graph showing the results of the combination of scRNA-seq data
763 and GWAS summary statistics on severe COVID-19 based on the RolyPoly among normal controls
764 and patients with different severities (i.e., mild, moderate, and severe). The y-axis shows the 13 cell
765 types, and x-axis shows mean negative log-transformation P value (-Log₂(P)). Orange color
766 indicates a cell type showing a significant association, and light blue represents there is no
767 significant association. B) UMAP projections of peripheral immune cells colored by annotated cell
768 types. The plot showing the region of CD16⁺monocytes, megakaryocytes, and memory CD8⁺T
769 cells. Red dot represents positive gene expressions of *CCR1*⁺, *ABO*⁺, and *CXCR6*⁺, and gray stands
770 for negative cells.

771

772 **Figure 4. *CCR1*⁺ CD16⁺monocytes contributes higher risk to cytokine storms among severe**
773 **COVID-19 patients.** A) Boxplot showing the difference in inflammatory cytokine score between
774 *CCR1*⁺ and *CCR1*⁻ CD16⁺ monocytes. Two-side Wilcoxon sum-rank test was used. B) Volcano
775 plot showing differentially expressed genes between *CCR1*⁺ and *CCR1*⁻ CD16⁺ monocytes. C)
776 Significantly enriched pathways by 351 highly-expressed genes among *CCR1*⁺ CD16⁺ monocytes.
777 Color legend represents the log transformed FDR value (-Log₁₀(FDR)). D) Bar graph showing the
778 proportion of *CCR1*⁺ CD16⁺ monocytes among normal, mild, moderate, and severe groups. E)
779 Boxplot showing the inflammatory cytokine score of *CCR1*⁺ CD16⁺ monocytes among normal,
780 mild, moderate, and severe groups. The Mann-Kendall trend analysis was used. F) Bar graph
781 showing the differentially up-DEGs among different COVID-19 patients compared with normal
782 controls. Namely, mild COVID-19 vs. normal, moderate COVID-19 vs. normal, and severe
783 COVID-19 vs. normal. Venn plot on top of bar showing the overlapped up-DEGs between moderate
784 and severe patients. G) The correlation of up-DEGs between moderate and severe patients. Pearson

785 correlation analysis was used to calculate the correlation coefficient and P value. H)-J)
786 Representative up-DEGs among *CCR1*⁺ CD16⁺ monocytes showing significantly elevated
787 expressions with increased COVID-19 severities. H) *S100A8*, I) *S100A9*, and J) *IFITM1*. K)
788 Disease-terms enrichment analysis on 190 up-DEGs based on the GLAD4U database. The y-axis
789 shows -Log₁₀(FDR), and x-axis shows the enrichment ratio.

790

791 **Figure 5. Multi-functionality of *CXCR6*⁺ memory CD8⁺T cells for severe COVID-19.** A)-D)

792 Boxplots showing the difference in (A) cytokine score, (B) chemokine score, (C) IFN- α/β response
793 score, and (D) T cell activation score between *CXCR6*⁺ and *CXCR6*⁻ memory CD8⁺T cells. Two-
794 side Wilcoxon sum-rank test was used. E) Volcano plot showing differentially expressed genes
795 between *CXCR6*⁺ and *CXCR6*⁻ memory CD8⁺T cells. F) Bar graph showing the proportion of
796 *CXCR6*⁺ memory CD8⁺T cells among normal, mild, moderate, and severe groups. G)-I) Boxplots
797 showing the (G) chemokine score, (H) T cell activation score, and (I) migration score of *CXCR6*⁺
798 memory CD8⁺T cells among normal, mild, moderate, and severe groups. The Mann-Kendall trend
799 analysis was used. J) Venn plot showing the overlapped up-DEGs between pairwise comparisons:
800 mild vs. normal, moderate vs. normal, and severe vs. normal. K) Representative gene of *GZMH*
801 among *CXCR6*⁺ memory CD8⁺T cells showing significantly elevated expressions with increased
802 COVID-19 severities. L) Heatmap showing up-DEGs in *CXCR6*⁺ memory CD8⁺T cells from
803 pairwise comparisons: mild vs. normal, moderate vs. normal, severe vs. normal. The up-DEGs
804 listed in the green panel were from mild vs. normal, yellow panel were from moderate vs. normal,
805 and orange panel were from severe vs. normal. M) Scatter plot showing the enriched GO biological
806 processes by 108 up-DEGs among *CXCR6*⁺ memory CD8⁺T cells. The x-axis shows -Log₁₀(FDR),
807 and y-axis shows the enrichment ratio.

808

809 **Figure 6. Cell-to-cell interactions of $CCR1^+$ $CD16^+$ monocytes and $CXCR6^+$ memory $CD8^+$ T**
810 **cells with other cells in PBMC and BALF.** A)-B) Boxplot showing the number of cellular
811 interactions of (A) $CCR1^+$ $CD16^+$ monocytes and (B) $CCR1^-$ $CD16^+$ monocytes with other immune
812 cells in PBMC between normal controls and patients with increased COVID-19 severities. C)
813 Predicted cellular interactions of $CCR1^+$ $CD16^+$ monocytes with other immune cells in PBMC,
814 comparing severe COVID-19 vs. normal control. D)-E) Boxplot showing the number of cellular
815 interactions of (D) $CXCR6^+$ memory $CD8^+$ T cells and (E) $CXCR6^-$ memory $CD8^+$ T cells with other
816 immune cells in PBMC between normal controls and patients with increased COVID-19 severities.
817 F) Predicted cellular interactions of $CXCR6^+$ memory $CD8^+$ T cells with other immune cells in
818 PBMC, comparing severe COVID-19 vs. normal control. G) Boxplot showing an increase in
819 cellular interactions with other cells in BALF for $CCR1^+$ $CD16^+$ monocytes than $CCR1^-$ $CD16^+$
820 monocytes. H) Predicted cellular interactions with other cells in BALF, comparing $CCR1^+$ $CD16^+$
821 monocytes with $CCR1^-$ $CD16^+$ monocytes. I) Boxplot showing an increase in cellular interactions
822 with other cells in BALF for $CXCR6^+$ memory $CD8^+$ T cells than $CXCR6^-$ memory $CD8^+$ T cells.
823 J) Predicted cellular interactions with other cells in BALF, comparing $CXCR6^+$ memory $CD8^+$ T
824 cells with $CXCR6^-$ memory $CD8^+$ T cells. The circular size represents the significance of each
825 ligand-receptor axis, and color represents the communication probability.

826

827 **References**

- 828 1. Dong E, Du H, Gardner L: **An interactive web-based dashboard to track COVID-19 in**
829 **real time.** *Lancet Infect Dis* 2020, **20**:533-534.
- 830 2. Wu Z, McGoogan JM: **Characteristics of and Important Lessons From the Coronavirus**
831 **Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases**
832 **From the Chinese Center for Disease Control and Prevention.** *JAMA* 2020.
- 833 3. Berlin DA, Gulick RM, Martinez FJ: **Severe Covid-19.** *N Engl J Med* 2020.
- 834 4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby
835 DP, Becker LB, Chelico JD, Cohen SL, et al: **Presenting Characteristics, Comorbidities,**
836 **and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York**
837 **City Area.** *JAMA* 2020, **323**:2052-2059.

- 838 5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et
839 al: **Clinical Characteristics of Coronavirus Disease 2019 in China.** *N Engl J Med* 2020,
840 **382**:1708-1720.
- 841 6. Xu L, Ma Y, Yuan J, Zhang Y, Wang H, Zhang G, Tu C, Lu X, Li J, Xiong Y, et al: **COVID-**
842 **19 Quarantine Reveals That Behavioral Changes Have an Effect on Myopia**
843 **Progression.** *Ophthalmology* 2021.
- 844 7. Pedersen SF, Ho YC: **SARS-CoV-2: a storm is raging.** *J Clin Invest* 2020, **130**:2202-2205.
- 845 8. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE,
846 Tokuyama M, et al: **Sex differences in immune responses that underlie COVID-19**
847 **disease outcomes.** *Nature* 2020, **588**:315-320.
- 848 9. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et
849 al: **Clinical and immunological features of severe and moderate coronavirus disease**
850 **2019.** *J Clin Invest* 2020, **130**:2620-2629.
- 851 10. Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, Voillet V, Duvvuri VR, Scherler K,
852 Troisch P, et al: **Multi-Omics Resolves a Sharp Disease-State Shift between Mild and**
853 **Moderate COVID-19.** *Cell* 2020, **183**:1479-1495.e1420.
- 854 11. Guo C, Li B, Ma H, Wang X, Cai P, Yu Q, Zhu L, Jin L, Jiang C, Fang J, et al: **Single-cell**
855 **analysis of two severe COVID-19 patients reveals a monocyte-associated and**
856 **tocilizumab-responding cytokine storm.** *Nat Commun* 2020, **11**:3924.
- 857 12. Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, et al: **COVID-**
858 **19 immune features revealed by a large-scale single-cell transcriptome atlas.** *Cell* 2021.
- 859 13. Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, Liu X, Xie L, Li J, Ye J, et al: **Immune**
860 **cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.** *Cell*
861 *Discov* 2020, **6**:31.
- 862 14. Zhang JY, Wang XM, Xing X, Xu Z, Zhang C, Song JW, Fan X, Xia P, Fu JL, Wang SY,
863 et al: **Single-cell landscape of immunological responses in patients with COVID-19.** *Nat*
864 *Immunol* 2020, **21**:1107-1118.
- 865 15. Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, Debnath O, Thürmann L,
866 Kurth F, Völker MT, et al: **COVID-19 severity correlates with airway epithelium-**
867 **immune cell interactions identified by single-cell analysis.** *Nat Biotechnol* 2020, **38**:970-
868 979.
- 869 16. Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almiré C, Hénon
870 C, Kosmider O, Droin N, et al: **Elevated Calprotectin and Abnormal Myeloid Cell**
871 **Subsets Discriminate Severe from Mild COVID-19.** *Cell* 2020, **182**:1401-1418.e1418.
- 872 17. Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, Krämer B,
873 Krammer T, Brumhard S, Bonaguro L, et al: **Severe COVID-19 Is Marked by a**
874 **Dysregulated Myeloid Cell Compartment.** *Cell* 2020, **182**:1419-1440 e1423.
- 875 18. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, Choi B, Nam SK, Sa M, Kwon JS, et
876 al: **Immunophenotyping of COVID-19 and influenza highlights the role of type I**
877 **interferons in development of severe COVID-19.** *Sci Immunol* 2020, **5**.
- 878 19. Cao X: **COVID-19: immunopathology and its implications for therapy.** *Nat Rev*
879 *Immunol* 2020, **20**:269-270.
- 880 20. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y,
881 Swartz TH, Madduri D, Stock A, et al: **An inflammatory cytokine signature predicts**
882 **COVID-19 severity and survival.** *Nat Med* 2020, **26**:1636-1643.
- 883 21. Arunachalam PS, Wimmers F, Mok CKP, Perera R, Scott M, Hagan T, Sigal N, Feng Y,
884 Bristow L, Tak-Yin Tsang O, et al: **Systems biological assessment of immunity to mild**
885 **versus severe COVID-19 infection in humans.** *Science* 2020, **369**:1210-1220.

- 886 22. **The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host**
887 **genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic.** *Eur*
888 *J Hum Genet* 2020, **28**:715-718.
- 889 23. Zhou S, Butler-Laporte G, Nakanishi T, Morrison DR, Afilalo J, Afilalo M, Laurent L,
890 Pietzner M, Kerrison N, Zhao K, et al: **A Neanderthal OAS1 isoform protects individuals**
891 **of European ancestry against COVID-19 susceptibility and severity.** *Nat Med* 2021,
892 **27**:659-667.
- 893 24. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S,
894 Parkinson N, Fourman MH, Russell CD, et al: **Genetic mechanisms of critical illness in**
895 **COVID-19.** *Nature* 2021, **591**:92-98.
- 896 25. Ma Y, Huang Y, Zhao S, Yao Y, Zhang Y, Qu J, Wu N, Su J: **Integrative Genomics**
897 **Analysis Reveals a 21q22.11 Locus Contributing Risk to COVID-19.** *Hum Mol Genet*
898 2021.
- 899 26. Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, Ho YL,
900 Iyengar SK, Kosik NM, Vujkovic M, et al: **Actionable druggable genome-wide**
901 **Mendelian randomization identifies repurposing opportunities for COVID-19.** *Nat*
902 *Med* 2021, **27**:668-676.
- 903 27. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernández J, Prati
904 D, Baselli G, Asselta R, et al: **Genomewide Association Study of Severe Covid-19 with**
905 **Respiratory Failure.** *N Engl J Med* 2020, **383**:1522-1534.
- 906 28. **Mapping the human genetic architecture of COVID-19.** *Nature* 2021.
- 907 29. Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, et al: **COVID-**
908 **19 immune features revealed by a large-scale single-cell transcriptome atlas.** *Cell* 2021,
909 **184**:1895-1913.e1819.
- 910 30. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R: **Integrating single-cell**
911 **transcriptomic data across different conditions, technologies, and species.** *Nat*
912 *Biotechnol* 2018, **36**:411-420.
- 913 31. Waltman L, van Eck NJ: **A smart local moving algorithm for large-scale modularity-**
914 **based community detection.** *The European Physical Journal B* 2013, **86**:471.
- 915 32. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M,
916 Loh PR, Raychaudhuri S: **Fast, sensitive and accurate integration of single-cell data with**
917 **Harmony.** *Nat Methods* 2019, **16**:1289-1296.
- 918 33. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL,
919 McCarthy S, McVean GA, Abecasis GR: **A global reference for human genetic variation.**
920 *Nature* 2015, **526**:68-74.
- 921 34. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis
922 GR, Willer CJ: **LocusZoom: regional visualization of genome-wide association scan**
923 **results.** *Bioinformatics* 2010, **26**:2336-2337.
- 924 35. de Leeuw CA, Mooij JM, Heskes T, Posthuma D: **MAGMA: generalized gene-set**
925 **analysis of GWAS data.** *PLoS Comput Biol* 2015, **11**:e1004219.
- 926 36. Wang J, Duncan D, Shi Z, Zhang B: **WEB-based GENE SeT AnaLysis Toolkit**
927 **(WebGestalt): update 2013.** *Nucleic Acids Res* 2013, **41**:W77-83.
- 928 37. Kanehisa M, Goto S: **KEGG: kyoto encyclopedia of genes and genomes.** *Nucleic Acids*
929 *Res* 2000, **28**:27-30.
- 930 38. Ma Y, Li J, Xu Y, Wang Y, Yao Y, Liu Q, Wang M, Zhao X, Fan R, Chen J, et al:
931 **Identification of 34 genes conferring genetic and pharmacological risk for the**
932 **comorbidity of schizophrenia and smoking behaviors.** *Aging (Albany NY)* 2020,
933 **12**:2169-2225.
- 934 39. Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, Torstenson
935 ES, Shah KP, Garcia T, Edwards TL, et al: **Exploring the phenotypic consequences of**


- 936 **tissue specific gene expression variation inferred from GWAS summary statistics.** *Nat*
937 *Commun* 2018, **9**:1825.
- 938 40. Barbeira AN, Pividori M, Zheng J, Wheeler HE, Nicolae DL, Im HK: **Integrating**
939 **predicted transcriptome from multiple tissues improves association detection.** *PLoS*
940 *Genet* 2019, **15**:e1007889.
- 941 41. Ma X, Wang P, Xu G, Yu F, Ma Y: **Integrative genomics analysis of various omics data**
942 **and networks identify risk genes and variants vulnerable to childhood-onset asthma.**
943 *BMC Med Genomics* 2020, **13**:123.
- 944 42. Xu M, Li J, Xiao Z, Lou J, Pan X, Ma Y: **Integrative genomics analysis identifies**
945 **promising SNPs and genes implicated in tuberculosis risk based on multiple omics**
946 **datasets.** *Aging (Albany NY)* 2020, **12**:19173-19220.
- 947 43. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B: **STRING: a database of**
948 **predicted functional associations between proteins.** *Nucleic Acids Res* 2003, **31**:258-261.
- 949 44. Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M: **STITCH 5:**
950 **augmenting protein-chemical interaction networks with tissue and affinity data.**
951 *Nucleic Acids Res* 2016, **44**:D380-384.
- 952 45. Calderon D, Bhaskar A, Knowles DA, Golan D, Raj T, Fu AQ, Pritchard JK: **Inferring**
953 **Relevant Cell Types for Complex Traits by Using Single-Cell Gene Expression.** *Am J*
954 *Hum Genet* 2017, **101**:686-699.
- 955 46. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ: **Second-generation**
956 **PLINK: rising to the challenge of larger and richer datasets.** *Gigascience* 2015, **4**:7.
- 957 47. Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV,
958 Nie Q: **Inference and analysis of cell-cell communication using CellChat.** *Nat Commun*
959 2021, **12**:1088.
- 960 48. Ghossaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, Fumis L,
961 Miranda A, Carvalho-Silva D, Buniello A, et al: **Open Targets Genetics: systematic**
962 **identification of trait-associated genes using large-scale genetics and functional**
963 **genomics.** *Nucleic Acids Res* 2021, **49**:D1311-d1320.
- 964 49. Battle A, Brown CD, Engelhardt BE, Montgomery SB: **Genetic effects on gene expression**
965 **across human tissues.** *Nature* 2017, **550**:204-213.
- 966 50. Wang Q, Chen R, Cheng F, Wei Q, Ji Y, Yang H, Zhong X, Tao R, Wen Z, Sutcliffe JS, et
967 al: **A Bayesian framework that integrates multi-omics data and gene networks predicts**
968 **risk genes from schizophrenia GWAS data.** *Nat Neurosci* 2019, **22**:691-699.
- 969 51. Ma Y, Li MD: **Establishment of a Strong Link Between Smoking and Cancer**
970 **Pathogenesis through DNA Methylation Analysis.** *Sci Rep* 2017, **7**:1811.
- 971 52. Auwul MR, Rahman MR, Gov E, Shahjaman M, Moni MA: **Bioinformatics and machine**
972 **learning approach identifies potential drug targets and pathways in COVID-19.** *Brief*
973 *Bioinform* 2021.
- 974 53. More SA, Patil AS, Sakle NS, Mokale SN: **Network analysis and molecular mapping for**
975 **SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.**
976 *Virology* 2021, **555**:10-18.
- 977 54. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, Petrey AC, Tolley
978 ND, Guo L, Cody M, et al: **Platelet gene expression and function in patients with**
979 **COVID-19.** *Blood* 2020, **136**:1317-1329.
- 980 55. Shaath H, Vishnubalaji R, Elkord E, Alajez NM: **Single-Cell Transcriptome Analysis**
981 **Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis**
982 **of Severe COVID-19.** *Cells* 2020, **9**.
- 983 56. Rydzynski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D,
984 Belanger S, Abbott RK, Kim C, Choi J, et al: **Antigen-Specific Adaptive Immunity to**

- 985 **SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.**
986 *Cell* 2020, **183**:996-1012.e1019.
- 987 57. King KR, Aguirre AD, Ye YX, Sun Y, Roh JD, Ng RP, Jr., Kohler RH, Arlauckas SP,
988 Iwamoto Y, Savol A, et al: **IRF3 and type I interferons fuel a fatal response to**
989 **myocardial infarction.** *Nat Med* 2017, **23**:1481-1487.
- 990 58. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, P é éH, Charbit B, Bondet
991 V, Chenevier-Gobeaux C, et al: **Impaired type I interferon activity and inflammatory**
992 **responses in severe COVID-19 patients.** *Science* 2020, **369**:718-724.
- 993 59. Lippi G, Plebani M, Henry BM: **Thrombocytopenia is associated with severe**
994 **coronavirus disease 2019 (COVID-19) infections: A meta-analysis.** *Clin Chim Acta* 2020,
995 **506**:145-148.
- 996 60. Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON,
997 Baltimore D, et al: **Multifunctional T-cell analyses to study response and progression**
998 **in adoptive cell transfer immunotherapy.** *Cancer Discov* 2013, **3**:418-429.
- 999 61. Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, Youngblood BA,
1000 Abdelsamed HA, McGuire DJ, Cohen KW, et al: **Origin and differentiation of human**
1001 **memory CD8 T cells after vaccination.** *Nature* 2017, **552**:362-367.
- 1002 62. Andrade F, Fellows E, Jenne DE, Rosen A, Young CS: **Granzyme H destroys the function**
1003 **of critical adenoviral proteins required for viral DNA replication and granzyme B**
1004 **inhibition.** *Embo j* 2007, **26**:2148-2157.
- 1005 63. Li Y, Hou G, Zhou H, Wang Y, Tun HM, Zhu A, Zhao J, Xiao F, Lin S, Liu D, et al: **Multi-**
1006 **platform omics analysis reveals molecular signature for COVID-19 pathogenesis,**
1007 **prognosis and drug target discovery.** *Signal Transduct Target Ther* 2021, **6**:155.
- 1008 64. Bruchez A, Sha K, Johnson J, Chen L, Stefani C, McConnell H, Gaucherand L, Prins R,
1009 Matreyek KA, Hume AJ, et al: **MHC class II transactivator CIITA induces cell**
1010 **resistance to Ebola virus and SARS-like coronaviruses.** *Science* 2020, **370**:241-247.
- 1011 65. Wein AN, McMaster SR, Takamura S, Dunbar PR, Cartwright EK, Hayward SL, McManus
1012 DT, Shimaoka T, Ueha S, Tsukui T, et al: **CXCR6 regulates localization of tissue-resident**
1013 **memory CD8 T cells to the airways.** *J Exp Med* 2019, **216**:2748-2762.
- 1014 66. Takamura S, Kato S, Motozono C, Shimaoka T, Ueha S, Matsuo K, Miyauchi K, Masumoto
1015 T, Katsushima A, Nakayama T, et al: **Interstitial-resident memory CD8(+) T cells sustain**
1016 **frontline epithelial memory in the lung.** *J Exp Med* 2019, **216**:2736-2747.
- 1017 67. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, Zhang Z, Liu L, Liu T, Liu Y, et al:
1018 **Relationship between the ABO Blood Group and the COVID-19 Susceptibility.** *Clin*
1019 *Infect Dis* 2020.
- 1020 68. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ,
1021 van Paassen J, Stals MAM, Huisman MV, Endeman H: **Incidence of thrombotic**
1022 **complications in critically ill ICU patients with COVID-19.** *Thromb Res* 2020, **191**:145-
1023 147.
- 1024 69. Grillet F, Behr J, Calame P, Aubry S, Delabrousse E: **Acute Pulmonary Embolism**
1025 **Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography.**
1026 *Radiology* 2020, **296**:E186-e188.
- 1027 70. Poran A, Harjanto D, Malloy M, Arieta CM, Rothenberg DA, Lenkala D, van Buuren MM,
1028 Addona TA, Rooney MS, Srinivasan L, Gaynor RB: **Sequence-based prediction of SARS-**
1029 **CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor**
1030 **identifies immunogenic T cell epitopes.** *Genome Med* 2020, **12**:70.
- 1031 71. Soudja SM, Ruiz AL, Marie JC, Lauvau G: **Inflammatory monocytes activate memory**
1032 **CD8(+) T and innate NK lymphocytes independent of cognate antigen during**
1033 **microbial pathogen invasion.** *Immunity* 2012, **37**:549-562.

- 1034 72. Ziegler-Heitbrock L: **The CD14+ CD16+ blood monocytes: their role in infection and**
1035 **inflammation.** *J Leukoc Biol* 2007, **81**:584-592.
- 1036 73. Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, Iwahashi M,
1037 Ueno A, Ohmoto Y, Makino H: **CD14+,CD16+ blood monocytes and joint inflammation**
1038 **in rheumatoid arthritis.** *Arthritis Rheum* 2002, **46**:2578-2586.
- 1039 74. Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad SM, Valappil M,
1040 McGovern N, Cant AJ, Hackett SJ, Ghazal P, et al: **STAT2 deficiency and susceptibility**
1041 **to viral illness in humans.** *Proc Natl Acad Sci U S A* 2013, **110**:3053-3058.
- 1042 75. Samji T, Khanna KM: **Understanding memory CD8(+) T cells.** *Immunol Lett* 2017,
1043 **185**:32-39.
- 1044 76. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L,
1045 Casellas R, et al: **c-Myc is a universal amplifier of expressed genes in lymphocytes and**
1046 **embryonic stem cells.** *Cell* 2012, **151**:68-79.
- 1047 77. Jouan Y, Guillon A, Gonzalez L, Perez Y, Boisseau C, Ehrmann S, Ferreira M, Daix T,
1048 Jeannet R, François B, et al: **Phenotypical and functional alteration of unconventional**
1049 **T cells in severe COVID-19 patients.** *J Exp Med* 2020, **217**.
- 1050 78. Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, Gazal S, Loh
1051 PR, Lareau C, Shores N, et al: **Heritability enrichment of specifically expressed genes**
1052 **identifies disease-relevant tissues and cell types.** *Nat Genet* 2018, **50**:621-629.
1053
- 1054


A

- **Four independent single cell RNA-seq datasets**



B

- **An increase in genetics-risk genes and cytokines for severe COVID-19**



C

- **Genetics-influenced immune cell subpopulations for severe COVID-19**




Figure 1




Figure 2





Figure 3




Figure 4




Figure 5




Figure 6